Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for REYATAZ
- A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions
- A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time
- Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
- Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients
- Atazanavir and Endothelial Function in Older HIV Patients
- Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen
- A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
- Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients
- ATAGLU: Study of Glucose Metabolism in HIV Positive Patients That Switch From Another Protease Inhibitor to Atazanavir
- Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study
- Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts
- RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients
- Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir
- Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients
- Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz
- Korean Post-marketing Surveillance for Reyataz®
- Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects
- Genetics and HIV-1 Protease Inhibitors
- HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
- Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients
- Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients
- Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection
- Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population
- Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users
- A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
- PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)
- Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
- IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults
- Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens
- The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia
- Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications
- Raltegravir and Atazanavir Dosing Strategy Study
- Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants
- Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults
- Pilot Study of a Raltegravir Based NRTI Sparing Regimen
- Phase IIB Pilot of Atazanavir + Raltegravir
- NNRTI/PI Toxicity Switch to Darunavir Study
- Drug Interaction Study
- Clinical Trial of CNS-targeted HAART (CIT2)
- Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)
- Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada
- DDI HV (ATV - Merck)
- SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
- Metabolic Effects of Switching Kaletra to Boosted Reyataz
- Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults
- Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis
- Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients
- Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone
- Atazanavir Twice Daily
- Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females
- Drug Interaction Study With Proton Pump Inhibitor
- Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects
- Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression
- Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women
- Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV
- BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada
- Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study
- Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)
- ATV/Ritonavir Nevirapine Interaction (USPAC)
- A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
- Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome
- Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir
- Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs
- A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy
- Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV
- Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
Clinical trials list
click for details